14 years strong: Northern California patient support group
On October 20th the Northern California Amyloidosis Support Group celebrated it’s fourteenth year with a meeting held at Stanford’s Blake Wilbur Cancer Center. (more…)
Tegsedi (Inotersen) approved by FDA for hATTR amyloidosis
The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy. (more…)
For many years, cardiac amyloid has had a few remarkable champions, preaching to half-empty rooms at medical conferences. Well, all that has changed. (more…)
Earlier this month, ARC CEO, Isabelle Lousada was among a small group of honorees named 2018 RARE Champion of Hope award recipients by Global Genes. (more…)
FDA approves first treatment for hereditary ATTR amyloidosis
The U.S. Food and Drug Administration today approved Patisiran, a novel therapy for the treatment of hereditary ATTR amyloidosis polyneuropathy. (more…)
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC TALKS webinar, Dr. Nativi-Nicolau and Dr. Elizabeth Mauricio discussed the decision pathway in management of ATTR amyloidosis from the cardiac and neurological standpoint.
Watch the recording to learn more about interdisciplinary approaches to ATTR amyloidosis care.
Original Presentation Date:
July 31, 2023
Key Webinar Highlights:
0:00 — Introduction
3:24 — Management of TTR amyloidosis (cardiac approaches)
8:37 — Constellation of symptoms checklist
16:43 — Disease modifying options in ATTR amyloidosis
22:22 — When should cardiology consult neurology?
24:42 — Management of TTR amyloidosis (neurologic manifestations)
28:11 — Investigating for neurologic manifestations
33:31 — Management of neuropathy
38:28 — Management of autonomic dysfunction
42:03 — Management of carpal tunnel syndrome
45:55 — Do hereditary and wild-type amyloidosis symptoms sort distinctly into neurologic and cardiac manifestations?
47:50 — How to tell the difference between diabetic and amyloid-related neuropathy?
48:36 — Is there a good approach to combination therapies?
51:06 — How to participate in clinical trials?
54:09 — Are there hereditary ATTR genes that haven’t been discovered?
56:14 — What’s the distinction between peripheral neuropathy and polyneuropathy?
58:07 — Are there any options for amyloid degraders?
1:00:29 — How can we raise awareness for earlier diagnosis?